Perkinelmer snaps up Biolegend
Perkinelmer has signed an agreement to acquire antibody- and reagent-maker
Biolegend for nearly $5.25 billion in cash and stock. Perkinelmer notes that the acquisition, which is subject to some adjustments, will be its largest so far. Biolegend delivers antibodies and reagents in cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing fields to its academic and biopharmaceutical clients. The company has about 700 employees, mainly based in the US. On concluding the acquisition, Biolegend will extend Perkinelmer’s current life science business into new areas. Perkinelmer anticipates the deal to help fasttrack discoveries in precision medicine.